rs116440799

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BA1BS2

This summary comes from the ClinGen Evidence Repository: The allele frequency of the c.61G>T variant in the ETHE1 gene is 0.7% in gnomAD, including 33 homozygotes which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen ETHE1 Variant Curation Expert Panel (>0.1% in gnomAD- BA1 and BS2). In summary, this variant meets criteria to be classified as benign for ETHE1-related ethylmalonic encephalopathy. ETHE1 specific ACMG/AMP criteria applied: (BA1, BS2). This was reviewed with the ETHE1 expert panel on 2/23/2021 and approved on 2/23/2021. LINK:https://erepo.genome.network/evrepo/ui/classification/CA290780/MONDO:0011229/014

Frequency

Genomes: 𝑓 0.018 ( 70 hom., cov: 32)
Exomes 𝑓: 0.0023 ( 79 hom. )

Consequence

ETHE1
NM_014297.5 missense

Scores

1
17

Clinical Significance

Benign reviewed by expert panel B:9

Conservation

PhyloP100: 0.802

Publications

5 publications found
Variant links:
Genes affected
ETHE1 (HGNC:23287): (ETHE1 persulfide dioxygenase) This gene encodes a member of the metallo beta-lactamase family of iron-containing proteins involved in the mitochondrial sulfide oxidation pathway. The encoded protein catalyzes the oxidation of a persulfide substrate to sulfite. Certain mutations in this gene cause ethylmalonic encephalopathy, an infantile metabolic disorder affecting the brain, gastrointestinal tract and peripheral vessels. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2016]
ZNF575 (HGNC:27606): (zinc finger protein 575) Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. [provided by Alliance of Genome Resources, Apr 2022]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BS2
For more information check the summary or visit ClinGen Evidence Repository.
BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ETHE1NM_014297.5 linkc.61G>T p.Ala21Ser missense_variant Exon 1 of 7 ENST00000292147.7 NP_055112.2 O95571A0A0S2Z5B3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ETHE1ENST00000292147.7 linkc.61G>T p.Ala21Ser missense_variant Exon 1 of 7 1 NM_014297.5 ENSP00000292147.1 O95571

Frequencies

GnomAD3 genomes
AF:
0.0185
AC:
2815
AN:
152234
Hom.:
70
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0618
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0114
Gnomad ASJ
AF:
0.000288
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.000470
Gnomad MID
AF:
0.00949
Gnomad NFE
AF:
0.000544
Gnomad OTH
AF:
0.0148
GnomAD2 exomes
AF:
0.00478
AC:
741
AN:
155116
AF XY:
0.00394
show subpopulations
Gnomad AFR exome
AF:
0.0638
Gnomad AMR exome
AF:
0.00540
Gnomad ASJ exome
AF:
0.000833
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000965
Gnomad OTH exome
AF:
0.00473
GnomAD4 exome
AF:
0.00233
AC:
3272
AN:
1404570
Hom.:
79
Cov.:
32
AF XY:
0.00213
AC XY:
1478
AN XY:
694728
show subpopulations
African (AFR)
AF:
0.0640
AC:
2052
AN:
32066
American (AMR)
AF:
0.00637
AC:
244
AN:
38276
Ashkenazi Jewish (ASJ)
AF:
0.000593
AC:
15
AN:
25296
East Asian (EAS)
AF:
0.00
AC:
0
AN:
36552
South Asian (SAS)
AF:
0.000124
AC:
10
AN:
80586
European-Finnish (FIN)
AF:
0.000288
AC:
12
AN:
41630
Middle Eastern (MID)
AF:
0.0124
AC:
70
AN:
5662
European-Non Finnish (NFE)
AF:
0.000479
AC:
520
AN:
1086128
Other (OTH)
AF:
0.00598
AC:
349
AN:
58374
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.474
Heterozygous variant carriers
0
184
368
551
735
919
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
82
164
246
328
410
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0185
AC:
2816
AN:
152350
Hom.:
70
Cov.:
32
AF XY:
0.0177
AC XY:
1322
AN XY:
74498
show subpopulations
African (AFR)
AF:
0.0617
AC:
2564
AN:
41582
American (AMR)
AF:
0.0114
AC:
175
AN:
15306
Ashkenazi Jewish (ASJ)
AF:
0.000288
AC:
1
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5182
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4832
European-Finnish (FIN)
AF:
0.000470
AC:
5
AN:
10630
Middle Eastern (MID)
AF:
0.0102
AC:
3
AN:
294
European-Non Finnish (NFE)
AF:
0.000544
AC:
37
AN:
68026
Other (OTH)
AF:
0.0147
AC:
31
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.498
Heterozygous variant carriers
0
142
284
425
567
709
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
30
60
90
120
150
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00661
Hom.:
10
Bravo
AF:
0.0216
ESP6500AA
AF:
0.0346
AC:
132
ESP6500EA
AF:
0.00116
AC:
9
ExAC
AF:
0.00425
AC:
482
Asia WGS
AF:
0.00375
AC:
14
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:9
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Ethylmalonic encephalopathy Benign:5
Nov 29, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 28, 2019
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

May 06, 2021
ClinGen Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel, ClinGen
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

The allele frequency of the c.61G>T variant in the ETHE1 gene is 0.7% in gnomAD, including 33 homozygotes which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen ETHE1 Variant Curation Expert Panel (>0.1% in gnomAD- BA1 and BS2). In summary, this variant meets criteria to be classified as benign for ETHE1-related ethylmalonic encephalopathy. ETHE1 specific ACMG/AMP criteria applied: (BA1, BS2). -

not provided Benign:3
Mar 16, 2016
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

May 21, 2015
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
Mar 17, 2014
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.074
BayesDel_addAF
Benign
-0.44
T
BayesDel_noAF
Benign
-0.36
CADD
Benign
12
DANN
Benign
0.70
DEOGEN2
Benign
0.20
T;.
Eigen
Benign
-1.1
Eigen_PC
Benign
-1.0
FATHMM_MKL
Benign
0.13
N
LIST_S2
Benign
0.57
T;T
MetaRNN
Benign
0.0022
T;T
MetaSVM
Benign
-0.78
T
MutationAssessor
Benign
0.34
N;.
PhyloP100
0.80
PrimateAI
Uncertain
0.61
T
PROVEAN
Benign
0.74
N;.
REVEL
Benign
0.21
Sift
Benign
1.0
T;.
Sift4G
Benign
0.88
T;T
Polyphen
0.0
B;.
Vest4
0.29
MVP
0.80
MPC
0.51
ClinPred
0.0018
T
GERP RS
3.0
PromoterAI
0.013
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.0
Varity_R
0.16
gMVP
0.47
Mutation Taster
=99/1
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs116440799; hg19: chr19-44031269; API